Company intelligence / Profile preview

SNIPR Biome

Ownership: Private
Employees: ~30
Development stage: Phase 1

Overview

SNIPR Biome was the first company to orally dose humans with a CRISPR therapeutic. Their lead candidate SNIPR001 has received FDA Fast Track Designation and is in Phase 1 clinical trials targeting E. coli in patients with hematological malignancy at risk of neutropenia[2][3].

Therapeutic areas: GastroenterologyOncologyInfectious Diseases
Modalities: CRISPR-based microbial gene therapy
Industry: Biotech

Drug pipeline

8 assets

SNIPR001

7 more assets in the full pipeline.

Request access →

Partnerships

Novo Nordisk A/SCARB-XBill & Melinda Gates FoundationSPRIN-DMD Anderson Cancer Center[3]

Beyond the preview

Go deeper on SNIPR Biome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNIPR Biome.

Explore the full profile